


PHARMACEUTICAL 2022

Paratek Pharmaceuticals Inc. Rank 414 of 466





DARATEK



PHARMACEUTICAL 2022



Paratek Pharmaceuticals Inc. Rank 414 of 466

The relative strengths and weaknesses of Paratek Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Paratek Pharmaceuticals Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 42% points. The greatest weakness of Paratek Pharmaceuticals Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 199% points.

The company's Economic Capital Ratio, given in the ranking table, is -113%, being 191% points below the market average of 78%.

| Input Variable | Value in 1000 USD |
|---|----------------------|
| Assets, Current | 152,100 |
| Cost of Goods Sold | 21,535 |
| Intangible Assets | 829 |
| Liabilities, Current | 31,297 |
| Liabilities, Non-Current | 258,513 |
| Other Assets | 30,146 |
| Other Compr. Net Income | -13 |
| Other Expenses | 18,008 |
| Other Liabilities | 21,846 |
| Other Net Income | 54 |
| Other Revenues | 130,162 |
| Property and Equipment | 794 |
| Research and Development | 30,353 |
| Selling, General and Administrative Expense | 119,404 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 183,869 |
| Liabilities | 311,656 |
| Expenses | 189,300 |
| Revenues | 130,162 |
| Stockholders Equity | -127,787 |
| Net Income | -59,084 |
| Comprehensive Net Income | -59,090 |
| Economic Capital Ratio | -113% |

